Bullpen.News From Edwin Dorsey
Get Daily Recap Feedback

Tuesday, August 18, 2026

Back to today

From X

@marginofdanger 1 click

marginofdanger on X

Ackman's closed end fund $PSUS will begin trading on Wednesday. For every 5 shares of PSUS, IPO investors (only) will get 1 share of $PS (the GP). It sounds like the PSUS offering will be 100mm shares at $50/share or $5 bn. Ackman thought this was going to be a $10 bn offering and he previously was targeting $25 bn or some ridiculous amount. The PSUS IPO investors will end up owning 20mm shares or 5% of PS (based on 400mm pf s/o). I expect that PSUS, like many closed end funds, will settle at a 5-10% discount to NAV, implying a trading price of $45-47.50/share. PS will begin trading as well (via a direct listing) and I anticipate a valuation of $5-10bn, implying that the PSUS IPO investors will get a "bonus" of $250-500mm on the $5 bn IPO or 5-10%. Therefore their loss on the PSUS shares should be mostly offset by the free shares in PS. Given this is a direct listing, I expect WILD price movements in PS stock and would stay far away from that one. I used $10 bn as the high end valuation for PS because that is where investors invested back a year or so ago (predicated upon significant growth in AUM), but I tend to believe that was a high watermark and not realistic given that Ackman can't seem to raise $. In terms of $PSUS, I don't see a compelling reason to own this at 90-95% of NAV. If you put a 15x on the 2% fee, that alone is a 30% drag. Also, Ackman has high volatility and there is no prospect to ever get repaid (and no incentive for Ackman to do so). Like $PSH.LN I would personally only step into $PSUS at a 25-30%+ discount to NAV and probably not in any real size.

Investor Letters

All letters

The AI Compute Squeeze

CoreWeave and Nebius cite AI compute shortages and higher-priced GPU renewals, but older-chip utilization and depreciation vary across…

CRWV $46BNBIS $60B
MBI Deep Dives 8 clicks
IQV · long

Iqvia Holdings INC

IQVIA runs drug trials and gets paid regardless of whether drugs pass, while trading at a COVID-low multiple with potential AI benefits.

IQV $42B
Value Investors Club 1 click

Publications we follow

Every publication on this site, hand-picked.

109 publications

Newsletters 92

YouTube 4

Blogs 12

Seeking Alpha 45 of 216

Nominate a publication

X accounts we follow

Every account on this site, hand-picked.

74 accounts
Nominate an account

Investor letters we follow

189 firms

Sectors

Ordered by how often our editor reaches for them.